Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on selpercatinib PK in healthy participants
NCT05324124Phase 1Completed
- Sponsor
- Loxo Oncology
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and thyroid cancer (2 arms), sponsored by Loxo Oncology. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at Day 8, Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value at Day 8 and 1 more. Started Apr 2022; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on NCT05324124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324124.